Clinical Trials

March 14, 2016 Cannabidiol Therapy Reduces Seizure Frequency in Dravet Syndrome Investigators have announced positive results for the first phase 3 clinical trial of GW Pharmaceutical’s cannabidiol therapy Epidiolex in patients with Dravet syndrome. The unpublished results mark a milestone for Epidiolex, which has already received Orphan Drug Designation and Fast Track Designation from the […]

by

WASHINGTON, March 14 (UPI) — The marijuana-based drug Epidiolex significantly reduced seizures in children with Dravet syndrome in a phase 3 clinical trial, lending scientific credence to a treatment used for several years but mostly supported by anecdotal evidence. GW Pharmaceuticals, which developed the drug, announced the results of the first of four trials with […]

by